Table 1. Demographic, medical, neuropsychological, and laboratory values for all subjects.
| HIV-infected (n=125) | HIV-uninfected (n=62) | P value a | |
|---|---|---|---|
| Demographics | |||
| Age [(years), mean (SD)] | 47.2 ± 12.2 | 45.4 ± 11.9 | 0.10 |
| Sex [n (% male)] | 80 (64) | 34 (55) | 0.27 |
| Education [(years), mean (SD)] | 14.4 ± 2.6 | 14.5 ± 2.2 | 0.25 |
| Ethnicity [n (%)] | 0.31 | ||
| African American | 84 (67) | 38 (62) | |
| Caucasian | 41 (33) | 24 (38) | |
| Past Substance Use b | |||
| Marijuana [n (%)] | 14 (11) | 3 (5) | 0.1 |
| Cocaine [n (%)] | 4 (3) | 0 (0) | 0.1 |
| Meth [n (%)] | 2 (2) | 1 (2) | 0.9 |
| Opiates [n (%)] | 2 (2) | 2 (3) | 0.3 |
| Alcohol [n (%)] | 10 (8) | 3 (5) | 0.4 |
| Clinical and Neuropsychological Characteristics | |||
| Estimated duration of HIV infection (years) | 10.5 ± 7.8 | NA | NA |
| % receiving highly active antiretroviral therapy (HAART) | 90 | NA | NA |
| Central Nervous System Penetration Effectiveness (CPE) Score [mean (SD)] | 6.70 ± 2.85 | NA | NA |
| Past hepatitis-C co-infection [n (%)] | 3 (2) | NA | NA |
| Neuropsychological Performance (Rasch Score) c | 0.14 ± 1.19 | 1.16 ± 1.08 | < 0.001 |
| Neuropsychological Performance (NPZ-4) c | -0.85 ± 1.27 | -0.14 ± 0.91 | < 0.001 |
| Laboratory | |||
| Current CD4 [(cells/μL), median (IQR)] | 533 (267, 724) | NA | NA |
| Nadir CD4 [(cells/μL), median (IQR)] | 189 (40, 308) | NA | NA |
| Median Log Plasma Viral Load [(copies/mL), median (IQR)] | 1.31 (1.30, 1.94) | NA | NA |
| % Virologically Suppressed (<50 copies/mL) | 75 | NA | NA |
a
Group comparisons using Student's t test (age, education, and neuropsychological performance (Rasch score and NPZ-4), and Fisher's exact test (gender, ethnicity, and past substance use).
b
History of past substance use based on participant self-report.
c
Higher scores indicate better performance on neuropsychological test